|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HTR4 |
Gene summary for HTR4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HTR4 | Gene ID | 3360 |
| Gene name | 5-hydroxytryptamine receptor 4 | |
| Gene Alias | 5-HT4 | |
| Cytomap | 5q32 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A2D3FAF9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3360 | HTR4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.56e-33 | -9.50e-01 | 0.0155 |
| 3360 | HTR4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.81e-11 | -7.42e-01 | -0.1808 |
| 3360 | HTR4 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.42e-02 | -8.07e-01 | 0.0216 |
| 3360 | HTR4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.53e-12 | -8.73e-01 | -0.0811 |
| 3360 | HTR4 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.52e-09 | -6.68e-01 | -0.1088 |
| 3360 | HTR4 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.32e-02 | -9.10e-01 | -0.2602 |
| 3360 | HTR4 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.75e-03 | -8.90e-01 | -0.2196 |
| 3360 | HTR4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.18e-13 | -8.54e-01 | -0.1207 |
| 3360 | HTR4 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.41e-08 | -6.41e-01 | -0.1526 |
| 3360 | HTR4 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.14e-30 | -7.60e-01 | -0.1464 |
| 3360 | HTR4 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.44e-22 | -6.99e-01 | -0.1001 |
| 3360 | HTR4 | HTA11_2992_2000001011 | Human | Colorectum | SER | 5.13e-05 | -8.89e-01 | -0.1706 |
| 3360 | HTR4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.10e-06 | -9.24e-01 | -0.2061 |
| 3360 | HTR4 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.55e-02 | -6.28e-01 | -0.0179 |
| 3360 | HTR4 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.15e-16 | -7.50e-01 | 0.096 |
| 3360 | HTR4 | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.42e-04 | -9.33e-01 | 0.0446 |
| 3360 | HTR4 | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.46e-06 | -8.82e-01 | 0.0528 |
| 3360 | HTR4 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.45e-02 | -7.68e-01 | 0.0131 |
| 3360 | HTR4 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.69e-12 | -8.36e-01 | 0.0338 |
| 3360 | HTR4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.63e-38 | -8.70e-01 | 0.0674 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
| GO:00316671 | Colorectum | SER | response to nutrient levels | 106/2897 | 474/18723 | 3.94e-05 | 1.00e-03 | 106 |
| GO:00316672 | Colorectum | MSS | response to nutrient levels | 125/3467 | 474/18723 | 1.24e-05 | 2.88e-04 | 125 |
| GO:00316673 | Colorectum | FAP | response to nutrient levels | 95/2622 | 474/18723 | 1.59e-04 | 2.43e-03 | 95 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04024 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
| hsa040241 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
| hsa040242 | Colorectum | CRC | cAMP signaling pathway | 47/1091 | 225/8465 | 4.57e-04 | 4.77e-03 | 3.23e-03 | 47 |
| hsa040243 | Colorectum | CRC | cAMP signaling pathway | 47/1091 | 225/8465 | 4.57e-04 | 4.77e-03 | 3.23e-03 | 47 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HTR4 | SNV | Missense_Mutation | rs764756332 | c.1238A>C | p.His413Pro | p.H413P | Q13639 | protein_coding | tolerated_low_confidence(0.21) | benign(0.255) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
| HTR4 | SNV | Missense_Mutation | rs764756332 | c.1238N>C | p.His413Pro | p.H413P | Q13639 | protein_coding | tolerated_low_confidence(0.21) | benign(0.255) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| HTR4 | SNV | Missense_Mutation | rs763453342 | c.1129N>A | p.His377Asn | p.H377N | Q13639 | protein_coding | tolerated_low_confidence(0.39) | possibly_damaging(0.888) | TCGA-OL-A6VO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| HTR4 | insertion | In_Frame_Ins | novel | c.651_652insCCTTTGGAA | p.Val217_Thr218insProLeuGlu | p.V217_T218insPLE | Q13639 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| HTR4 | deletion | Frame_Shift_Del | novel | c.648delN | p.Tyr216Ter | p.Y216* | Q13639 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| HTR4 | SNV | Missense_Mutation | rs140360260 | c.691C>T | p.Arg231Trp | p.R231W | Q13639 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| HTR4 | SNV | Missense_Mutation | novel | c.511G>C | p.Glu171Gln | p.E171Q | Q13639 | protein_coding | tolerated(0.27) | benign(0.05) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| HTR4 | SNV | Missense_Mutation | c.1018N>G | p.Leu340Val | p.L340V | Q13639 | protein_coding | deleterious(0.03) | benign(0.103) | TCGA-LP-A4AX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HTR4 | SNV | Missense_Mutation | rs186099216 | c.409C>T | p.Arg137Cys | p.R137C | Q13639 | protein_coding | tolerated(0.14) | probably_damaging(0.999) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| HTR4 | SNV | Missense_Mutation | rs201201172 | c.1084N>A | p.Val362Ile | p.V362I | Q13639 | protein_coding | tolerated_low_confidence(0.18) | benign(0.009) | TCGA-AA-A01T-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | SB-207266A | |||
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | ZOLMITRIPTAN | ZOLMITRIPTAN | ||
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 315661144 | PF-04995274 | |
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650947 | ||
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 135650983 | ||
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135649998 | ||
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 178100293 | ||
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | partial agonist | CHEMBL1516474 | TEGASEROD MALEATE | |
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | partial agonist | CHEMBL2027925 | CAPESEROD | |
| 3360 | HTR4 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | PRX-3140 |
| Page: 1 2 3 4 5 6 7 8 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |